
zzso reduce the risk of zzso events zzso zzso spinal zzso zzso pathological zzso radiation or surgery to the bone, and zzso in patients with zzso zzso A number of analyses have been conducted to assess the cost effectiveness of zzso in patients with bone zzso secondary to breast cancer, but few in other solid zzso This is a review of zzso analyses in patients with zzso solid zzso and bone zzso A literature search was conducted to identify zzso analyses reporting the cost per zzso gained of zzso in patients with zzso bone disease secondary to zzso solid zzso Four analyses met inclusion zzso These included two in prostate cancer (one of which used a global perspective but expressed results in zzso and the other reported from a multiple country perspective: France, Germany, zzso and the zzso The remaining analyses were in lung cancer (in the zzso France, Germany, zzso and the zzso and zzso cell zzso (in the zzso France and zzso In each analysis, the cost effectiveness of zzso acid versus zzso was zzso zzso acid was found to be cost effective in all European countries across all three indications but not in the sole global prostate cancer zzso Across countries and zzso assumptions regarding patient survival, drug cost and baseline utility zzso patient utility with zzso disease but without an zzso were the most robust drivers of zzso zzso zzso of zzso costs were most often the second strongest cost zzso Further review indicated that particular attention should be paid to the inclusion or exclusion of zzso survival benefits, whether health state utilities were zzso from community or patient samples or author zzso zzso between symptomatic and zzso zzso and the methods with which zzso zzso was zzso over zzso While the field of zzso analysis in solid zzso other than breast cancer is still evolving, outcomes will likely continue to be driven by drug cost and assumptions regarding treatment zzso Although considerations such as adverse events and administration costs are important, they were not found to influence zzso estimates zzso As zzso acid will lose patent protection in 2013 and subsequently be greatly reduced in price, it is likely that the field of cost effectiveness will change with regard to zzso zzso Meanwhile, research should be conducted to improve our understanding of the impact on quality of life and medical costs of preventing zzso 

